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A B S T R A C T
Purpose
To determine the 12-year risk of developing an ipsilateral breast event (IBE) for women with ductal
carcinoma in situ (DCIS) of the breast treated with surgical excision (lumpectomy) without radiation.
Patients and Methods
A prospective clinical trial was performed for women with DCIS who were selected for
low-risk clinical and pathologic characteristics. Patients were enrolled onto one of two study
cohorts (not randomly assigned): cohort 1: low- or intermediate-grade DCIS, tumor size 2.5 cm
or smaller (n  561); or cohort 2: high-grade DCIS, tumor size 1 cm or smaller (n  104).
Protocol specifications included excision of the DCIS tumor with a minimum negative margin
width of at least 3 mm. Tamoxifen (not randomly assigned) was given to 30% of the patients.
An IBE was defined as local recurrence of DCIS or invasive carcinoma in the treated breast.
Median follow-up time was 12.3 years.
Results
There were 99 IBEs, of which 51 (52%) were invasive. The IBE and invasive IBE rates increased
over time in both cohorts. The 12-year rates of developing an IBE were 14.4% for cohort 1 and
24.6% for cohort 2 (P  .003). The 12-year rates of developing an invasive IBE were 7.5% and
13.4%, respectively (P  .08). On multivariable analysis, study cohort and tumor size were both
significantly associated with developing an IBE (P  .009 and P  .03, respectively).
Conclusion
For patients with DCIS selected for favorable clinical and pathologic characteristics and treated
with excision without radiation, the risks of developing an IBE and an invasive IBE increased
through 12 years of follow-up, without plateau. These data help inform the treatment decision-
making process for patients and their physicians.
J Clin Oncol 33:3938-3944. © 2015 by American Society of Clinical Oncology
INTRODUCTION
The optimal clinical management for women with
newly diagnosed ductal carcinoma in situ (DCIS;
intraductal carcinoma)of thebreast is controversial,
with variable patterns of practice.1-7 Althoughmost
women with DCIS of the breast present with an
asymptomatic finding on routine screening
mammography, population-based studies dem-
onstrate awide range of treatments.4-7 Local treat-
ment options for DCIS include surgical excision
(lumpectomy) with or without radiation treat-
ment, unilateral mastectomy, and even bilateral
mastectomies. Systemic therapy options include
adjuvant tamoxifen for hormone receptor–positive
DCIS tumors. In randomized clinical trials, add-
ing radiation treatment or tamoxifen after
lumpectomy has been shown to reduce recur-
rence rates, with low rates of distant metastases
and high rates of overall survival (OS), regardless
of initial treatment.8-19
The Eastern Cooperative Oncology Group–
American College of Radiology Imaging Network
(ECOG-ACRIN; formerly the Eastern Cooperative
Oncology Group) Cancer Research Group E5194
study prospectively enrolled onto a nonrandomized
clinical trial those patients for whom surgical exci-
sion alone (without radiation) was thought to be a
reasonable treatment option on the basis of low-risk
clinical and pathologic characteristics. A previous
analysis from the ECOG-ACRIN E5194 study re-
ported5-and7-yearoutcomes.20Thepresent report
provides updated results from the ECOG-ACRIN
E5194 study, including 10- and 12-year outcomes.
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PATIENTS AND METHODS
Study Design
The ECOG-ACRIN E5194 study was a prospective, nonrandomized
clinical trial. Patientswere enrolledontoprotocol throughECOG-ACRINand
the North Central Cancer Treatment Group (now part of the Alliance for
Clinical Trials in Oncology) from April 1997 to October 2002. The study
protocol was approved by the respective institutional review boards of the
participating centers at which the patients were enrolled. All patients gave
written informed consent.
Detailed informationon the trialdesignandconducthaspreviouslybeen
reported.20,21 A brief summary is as follows. The protocol study included two
cohorts of patients (not randomly assigned) with low-risk clinical and patho-
logic characteristics: cohort1: low-or intermediate-gradeDCIS, tumor size2.5
cm or smaller (cohort 1; n  561 patients); or cohort 2: high-grade DCIS,
tumor size 1 cm or smaller (cohort 2; n 104 patients). Cohort assignment
and study enrollment were based on clinical evaluation and pathology assess-
ment from the treating institution.
All patients underwent surgical excision (lumpectomy) of the primary
DCIS tumor. Protocol specifications included surgical excision with a mini-
mumnegativemarginwidth of at least 3mmor no tumor on re-excision. The
surgical specimenwas sequentially sectioned and completely embedded at the
treating institution to determine the pathologic characteristics of the DCIS
tumor.Hormone receptor statuswasnot collectedat the timeof study entry.A
negative postoperative mammogram was required for any patient presenting
with suspicious calcifications on preoperative mammography. Radiation
treatment was not allowed. In May 2000, the study was amended to allow
treatmentwithadjuvant tamoxifen inanoptional, nonrandomized fashion. In
the event of disease recurrence or progression, treatment was given at the
discretion of the treating physicians.
A total of 665 patients were evaluated for the present analysis (n 561
patients in cohort 1; and n 104 patients in cohort 2). After the first report of
the E5194 study, subsequent central pathology review determined that five
patients had invasive carcinoma, and these patients were excluded from the
present analysis. Evaluation of the study results either with or without inclu-
sion of these five patients did not differ substantially (data not shown).
Pathology Evaluation
Pathology findings have been scored in three ways. First, pathology
findings were recorded from the institutional pathology assessment on entry
into the parent study protocol. Second, in the parent study, central pathology
review (also referred to as the first central pathology review) was performed
using previously specified criteria.22 Tumor size was evaluated on central
pathology reviewof 601patients (n501 for cohort 1; andn100 for cohort
2).Thereafter, theCollegeofAmericanPathologists (CAP)publishedanewset
of guidelines for reportingDCIS tumor specimens, nowwidely used in clinical
practice.23 Using the CAP guidelines, a second central pathology review was
performed concurrently by two expert breast pathologists (S.S.B. and F.L.B.)
to characterize theDCIS tumors of 500 patients (75%of the overall group) for
whom pathology specimens were available (Appendix, online only).24
Statistical Methods
The primary end point of the study was an ipsilateral breast event (IBE).
An IBEwas defined as the first local recurrence ofDCIS or invasive carcinoma
in the treated (ipsilateral) breast. In addition to the primary end point of any
IBE, separate analyseswerealsoperformed for the subsetsof invasive IBE(with
or without associated DCIS) and DCIS-only IBE. The time to an IBE was
defined as the time from the last (definitive) surgery until the first evidence of
an IBE.
The Kaplan-Meier method was used to estimate time to event distribu-
tions. SEswere estimatedusing theGreenwood formula.CIswere constructed
using the normal approximation on the probability scale, and are given at the
95% level. Cox proportional hazard methods were used to estimate hazard
ratios (HRs) and tests for significance for event times. All P values are two-
sided. Tamoxifen use was considered as a time-dependent covariate.
Follow-up cutoff was at the time of last reported disease evaluation, ipsilateral
mastectomy, initiationofchemotherapy,ordeath.Themedian follow-uptime
was 12.3 years, with 346 patients and 217 patients observed for at least 10 and
12 years, respectively.
RESULTS
Patient, Tumor, and Treatment Characteristics
Table 1 details patient, tumor, and treatment characteristics. The
patients enrolled onto study showed generallymore favorable clinical
and pathologic characteristics than required by the study protocol.
Themedian tumor sizewas 6mmfor cohort 1 and7mmfor cohort 2.
The minimum negative margin width was 5 mm or greater for 64%
and 69% of the patients in each cohort, respectively, and 10 mm or
greater for 21% and 24% of the patients, respectively. The median
patient age was 60 years and 58 years, respectively. Tamoxifen was
given in a nonrandomized fashion to 30% of the patients (31% for
cohort 1% and 24% for cohort 2).
IBEs and Other Outcomes
Overall, therewere 99 IBEs (n 74 in cohort 1; n 25 in cohort
2), ofwhich51 (52%)were an invasive IBE (n39 in cohort 1; n12
in cohort 2). The 12-year rates of developing an IBE were 14.4% for
cohort 1 and 24.6% for cohort 2 (P .003; Fig 1 and Table 2). The
12-year rates for developing an invasive IBE were 7.5% and 13.4%,
respectively (P .08; Fig 1 and Table 3). The risks of developing an
IBE and an invasive IBE increased over time through 12 years of
follow-up,withoutplateau.For cohort 1, the rateofdevelopingan IBE
was approximately 1.2%per year through year 12, and for an invasive
IBE, approximately 0.6% per year through year 12. No differences
were seen between the two cohorts for the 12-year rates of OS (84.0%
v 82.8%;P .96) or contralateral breast cancer events (6.7% v 12.0%;
P .16; Appendix Table A1, online only).
The rates of developing an IBE and an invasive IBE as a function
of clinically relevant subsets of patients are shown in Tables 2 and 3,
respectively. Tumor size was statistically significantly associated with
developing an IBE (P .01; Fig 2 and Table 2). The results of similar
analyses restricted to the patients enrolled in cohort 1 are given in
Appendix Tables A2 and A3 (online only).
We found that studycohort and tumor sizewereboth statistically
significantly associated with developing an IBE using multivariable
Cox proportional hazardsmodel. The hazard ratio (HR) for cohort 2
was 1.84 compared with cohort 1 (P .009). Using a tumor size of 5
mmor less as the reference group, theHRswere 1.42 (95%CI, 0.88 to
2.29) for tumor size 6 to 10 mm and 2.11 (95% CI, 1.23 to 3.62) for
tumor size greater than 10 mm (P  .03). Variables not statistically
significant were age, menopausal status, minimum negative margin
width, method of detection, bloody nipple discharge, tamoxifen use,
and prior hormone therapy (all P .25). The HR for tamoxifen use
(comparedwithno tamoxifenuse)was0.66 (95%CI,0.40 to1.06;P
.09) with tamoxifen evaluated as a single variable in a proportional
hazards model.
By using a multivariable Cox proportional hazards model for
developing an invasive IBE, we found that only the study cohort was
borderline significant (P .08). No other factor was statistically sig-
nificant (all P .26).
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Table 1. Patient, Tumor, and Treatment Characteristics
Characteristic
Cohort 1,a
No. (%)
(n  561)
Cohort 2,a
No. (%)
(n  104)
Age, years
 39 13 (2) 4 (4)
40-49 93 (17) 21 (20)
50-59 166 (30) 30 (29)
60-69 146 (26) 28 (27)
 70 143 (25) 21 (20)
Race/ethnicityb
White 519 (93) 95 (95)
Hispanic 8 (1) 1 (1)
Black 16 (3) 4 (4)
Other 14 (3) 0 (0)
Menopausal statusc
Premenopausal 134 (24) 29 (28)
Postmenopausal 427 (76) 75 (72)
Tumor size, mmd
 5 226 (40) 28 (27)
6-10 231 (41) 61 (59)
 10 104 (19) 15 (14)
Minimum negative margin width, mm
 1e 9 (2) 2 (2)
1-2.9e 10 (2) 2 (2)
3-4.9 184 (33) 28 (27)
5-9.9 239 (43) 47 (45)
 10f 119 (21) 25 (24)
Method of detectionb
Microcalcifications 399 (71) 88 (85)
Density or mass 93 (17) 4 (4)
Both 40 (7) 7 (7)
Incidental finding 19 (3) 5 (5)
Other 8 (1) 0 (0)
Bloody nipple dischargeb
Yes 12 (2) 1 (1)
No 541 (98) 102 (99)
Tamoxifen use
Yes 174 (31) 25 (24)
No 387 (69) 79 (76)
Hormone replacement therapy before study entryb
Yes 239 (43) 47 (45)
No 315 (57) 57 (55)
Treating institution gradeg
Low 281 (50) 0 (0)
Intermediate 280 (50) 0 (0)
High 0 (0) 104 (100)
CAP gradeh
Low 61 (15) 2 (2)
Intermediate 249 (59) 19 (24)
High 110 (26) 59 (74)
Abbreviation: CAP, College of American Pathologists.
aCohort 1 defined as low- or intermediate-grade ductal carcinoma in situ
(DCIS), tumor size 2.5 cm or smaller. Cohort 2 defined as high-grade DCIS,
tumor size 1.0 cm or smaller. Cohort assignment was based on clinical
evaluation and pathology assessment from the treating institution at the
time of enrollment onto the study.
bUnknown cases and cases that were not evaluated were excluded.
cPatients younger than age 50 years were assumed to be premenopausal
when menopausal status was not recorded.
dTumor size was based on central pathology review, when this information was
available.
eCases with negative margin width less than 3 mm were determined on
central pathology review.
fCases with no tumor on re-excision are included.
gGrade as determined on pathology assessment from the treating institution
at the time of enrollment onto study.
hGrade as determined on central pathology review using current CAP
guidelines. Cases that were not evaluated were excluded.
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Fig 1. Ipsilateral breast events (IBEs) for cohort 1 and cohort 2. Cohort 1 was
defined as low- or intermediate-grade ductal carcinoma in situ (DCIS), tumor size
2.5 cm or smaller. Cohort 2 was defined as high-grade DCIS, tumor size 1.0 cm
or smaller. Cohort assignment was based on clinical evaluation and pathology
assessment from the treating institution at the time of enrollment. The numbers
at risk are given beneath the x-axis. (A) Any IBE. (B) Subset of invasive IBE. (C)
Subset of DCIS-only IBE.
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Central Pathology Evaluation
For the subset of 500 patients for which central pathology review
had been performed using current CAP guidelines for DCIS, the
12-year rates of developing an IBE were 12.5% for low-grade DCIS,
15.1% for intermediate-grade DCIS, and 20.6% for high-grade DCIS
(P .16;Table 2 andAppendixFigA1, onlineonly).The12-year rates
of developing an invasive IBE were 5.5%, 6.7%, and 11.7%, respec-
tively (P .19; Table 3 and Appendix Fig A1). Comedo necrosis and
the University of Southern California/Van Nuys Prognostic Index
(USC/VNPI)were not significantly associatedwith developing an IBE
or invasive IBE (all P  .13).25 Appendix Tables A4 and A5 (online
only) show analyses of IBE rates that compare current CAP grading
Table 2. IBE Rates for Clinically Relevant Subsets of Patients
Variable No. of Patients
5 Years 10 Years 12 Years
P% 95% CI % 95% CI % 95% CI
Cohort 1 561 6.0 4.0 to 8.1 12.5 9.5 to 15.4 14.4 11.2 to 17.6 .003
Cohort 2 104 15.0 8.0 to 22.0 24.6 15.7 to 33.4 24.6 15.7 to 33.4
Age, years
 49 131 11.7 6.2 to 17.3 16.8 10.3 to 23.4 18.9 11.9 to 26.0 .51
50-69 370 6.0 3.5 to 8.5 13.5 9.8 to 17.2 15.1 11.2 to 19.0
 70 164 7.1 3.1 to 11.2 14.1 8.1 to 20.1 15.7 9.0 to 22.3
Minimum negative margin width, mm
 5 235 7.6 4.1 to 11.1 14.9 10.0 to 19.7 17.0 11.7 to 22.2 .85
5-9 286 7.1 4.0 to 10.1 13.5 9.2 to 17.8 15.2 10.6 to 19.8
 10 144 8.0 3.5 to 12.6 15.3 9.1 to 21.5 16.3 9.9 to 22.8
Tumor size, mm
 5 254 6.1 3.1 to 9.2 10.7 6.7 to 14.7 11.3 7.2 to 15.4 .01
6-10 292 6.6 3.7 to 9.6 15.5 11.0 to 20.0 17.8 12.9 to 22.7
 10 119 12.5 6.4 to 18.6 20.0 12.3 to 27.8 22.9 14.5 to 31.3
CAP grade†
Low 63 5.1 0 to 10.8 12.5 3.8 to 21.3 12.5 3.8 to 21.3 .16
Intermediate 268 6.3 3.3 to 9.4 13.2 8.9 to 17.6 15.1 10.4 to 19.9
High 169 11.1 6.2 to 15.9 20.6 14.2 to 27.0 20.6 14.2 to 27.0
Abbreviations: CAP, College of American Pathologists; IBE, ipsilateral breast event.
Tumor size was based on central pathology review, when this information was available. Results are similar for tumor size on the basis of institutional pathology
assessment at enrollment onto the study (P  .03; data not shown).
†Restricted to the subset of 500 cases for which a central pathology review was performed using current CAP guidelines.
Table 3. Invasive IBE Rates for Clinically Relevant Subsets of Patients
Variable No. of Patients
5 Years 10 Years 12 Years
P% 95% CI % 95% CI % 95% CI
Cohort 1 561 2.7 1.3 to 4.1 6.4 4.2 to 8.6 7.5 5.1 to 10.0 .08
Cohort 2 104 5.3 0.8 to 9.7 13.4 5.9 to 20.9 13.4 5.9 to 20.9
Age, years
 49 131 4.8 1.1 to 8.6 8.5 3.4 to 13.5 9.6 4.1 to 15.0 .43
50-69 370 3.4 1.5 to 5.4 7.6 4.7 to 10.5 8.8 5.7 to 12.0
 70 164 0.7 0 to 2.1 6.2 1.7 to 10.8 6.2 1.7 to 10.8
Minimum negative margin width, mm
 5 235 2.8 0.6 to 4.9 8.1 4.3 to 11.9 8.1 4.3 to 11.9 .64
5-9 286 3.4 1.2 to 5.5 7.8 4.4 to 11.3 9.6 5.7 to 13.4
 10 144 3.1 0.1 to 6.0 5.6 1.6 to 9.6 6.7 2.2 to 11.2
Tumor size, mm
 5 254 2.5 0.5 to 4.5 6.3 3.1 to 9.5 6.3 3.1 to 9.5 .40
6-10 292 2.9 0.9 to 4.9 8.5 5.0 to 12.0 10.3 6.3 to 14.3
 10 119 4.8 0.7 to 8.8 7.2 2.0 to 12.4 8.7 2.8 to 14.6
CAP grade†
Low 63 1.8 0 to 5.3 5.5 0 to 11.6 5.5 0 to 11.6 .19
Intermediate 268 2.0 0.3 to 3.8 5.4 2.4 to 8.4 6.7 3.2 to 10.1
High 169 4.5 1.2 to 7.7 11.7 6.4 to 17.0 11.7 6.4 to 17.0
Abbreviations: CAP, College of American Pathologists; IBE, ipsilateral breast event.
Tumor size was based on central pathology review, when this information was available. Results are similar for tumor size on the basis of institutional pathology
assessment at enrollment onto the study (P  .40; data not shown).
†Restricted to the subset of 500 cases for which a central pathology review was performed using current CAP guidelines.
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with older grading classifications. Fewer DCIS tumors were classi-
fied as low grade using CAP guidelines compared with older grad-
ing classifications.
DISCUSSION
This study has demonstrated that for patients with favorable DCIS
who were selected on the basis of clinical and pathologic characteris-
tics and treated with surgical excision without radiation, the risks of
developing an IBEandan invasive IBE increasedover time through12
years of follow-up (Fig 1 and Tables 2 and 3). The 12-year rates of
developing an IBE were 14.4% for cohort 1 and 24.6% for cohort 2
(P .003; Fig 1 and Table 2), and the 12-year rates of developing an
invasive IBE were 7.5% and 13.4%, respectively (P  .08; Fig 1 and
Table 3). No clearly defined plateau was observed for either cohort of
patients. Individual patients and their physicianswill need to decide if
these 12-year risks are acceptable, andwhetherornot to foregoadding
adjuvant treatment after surgical excision.
The ECOG-ACRIN E5194 study was a nonrandomized, pro-
spective clinical trial for women with DCIS who were selected for
low-risk clinical and pathologic features as identified at the time of
enrollment. The majority of enrolled patients were postmenopausal
and had small (tumor size  1 cm), mammographically detected
DCIS excised with negative margins of resection (Table 1). These
characteristics are similar to those of patients with DCIS in
population-based studies.4,5 Therefore, the findings in this study are
relevant to contemporary practice.
The optimal treatment for women with newly diagnosed DCIS
continues tobedebated.National guidelines in theUnitedStates allow
for awide rangeof local treatment options, including surgical excision
(lumpectomy) with or without radiation, unilateral mastectomy, and
even bilateral mastectomies,26,27 but no consensus approach has de-
veloped. For patients considered low risk, national guidelines include
theoption for surgical excisionalone (without radiation)asacceptable
local treatment, althoughwhat constitutes low risk is notwell defined.
Five randomized clinical trials have consistently demonstrated that
adding radiation treatment after surgical excision for patients withDCIS
reduces the risk of local recurrence in the ipsilateral breast by approxi-
mately half.8-16 The Early Breast Cancer Trialists’ Collaborative Trial
Group (EBCTCG) meta-analysis combined data from four of the ran-
domized trials of radiation treatment after surgical excision.17 Two ran-
domized clinical trials have demonstrated that adding tamoxifen reduces
the risk of all breast cancer events (ipsilateral plus contralateral) for hor-
mone receptor–positiveDCIS tumors.9,10,14,18,19 Although the risk of re-
currence is decreased by adding radiation and tamoxifen after surgical
excision, no improvement in the rates of distantmetastases andOShave
been shown in any randomized clinical trial.
The risk of local recurrence after surgical excisionwithout radia-
tion has been reported in a number of randomized and nonrandom-
ized, prospective clinical trials.8-16,28 The increasing risk of local
recurrence over time as seen in the current analysis of ECOG-ACRIN
E5194 is consistent with other prospective studies, both randomized
and nonrandomized. For patients treated with surgical excisionwith-
out radiation in randomized clinical trials, the 10-year rate of local
recurrence has been reported as approximately 24% to 30%.9,11,14,15
In the randomized RTOG 9804 study, adding radiation treatment
after lumpectomy reduced the 7-year rate of local recurrence from
6.7% to 0.9% (P .001).16 In a nonrandomized, prospective study,
Wong et al28 reported that the 10-year rate of local recurrence was
15.6% after surgical excision without radiation. The various prospec-
tive clinical trials differ with respect to a number of protocol-defined
parameters (eg, tumor grade, definition of negative surgical margins,
useof tamoxifen),whichmay, at least inpart, account for the reported
differences seen in local recurrence rates between studies.
Even though the riskof recurrence is reducedbyadding radiation
and tamoxifen after surgical excision, ongoing efforts continue in an
attempt to identify patientswith favorable disease at presentationwho
have a sufficiently low risk of local recurrence after surgical excision
that omitting adjuvant therapy is reasonable. Themajority of women
with DCIS present with an asymptomatic finding of microcalcifica-
tions on routine screening mammography. As most women with
newly diagnosed DCIS are eligible for breast conservation surgery, an
important aspect of clinical decisionmaking is oftenwhether ornot to
add radiation treatment, which includes an assessment of the risks of
developing a local recurrence and an invasive local recurrence after
surgical excision alone without radiation. The lack of survival benefit
fromadding adjuvant treatments and the small, but real, potential risk
of adverse effects are reasons commonly given to omit adjuvant treat-
ments (radiationandtamoxifen)after surgical excision.Therefore, the
risk-benefit ratiomay favor omitting adjuvant treatment if a cohort of
patients could be prospectively identified at presentation with a suffi-
ciently low risk of recurrence after surgical excision alone.
Pathologic grade commonly influences clinicalmanagement de-
cisions for the treatment of DCIS. Since the design of this study,
guidelines for determining the grade of DCIS have changed, resulting
in fewer DCIS tumors classified as low grade (Table 1). In this study,
CAP grading was not associated with the risks of developing a local
recurrence and an invasive local recurrence, and thus, is not clinically
useful in identifying a low-risk cohort of patients (Tables 2 and 3;
Appendix Fig A1).
Early efforts to identify a cohort of patients with low-risk disease
focused on using clinical and pathologic characteristics. However,
prospective clinical trials, randomized and nonrandomized, have not
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Fig 2. Ipsilateral breast events (IBEs) according to tumor size. The numbers at
risk are given beneath the x-axis.
Solin et al
3942 © 2015 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Downloaded from ascopubs.org by INDIANA University ACQ DEPT on April 9, 2019 from 134.068.173.162
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
reproducibly and reliably identified patients with low-risk DCIS, es-
pecially with long-term follow-up of at least 10 years. More recent
efforts have focused onusingmolecularmarkers to determine the risk
of recurrence after surgical excision.21,29-33 The value of molecular
markers comparedwith traditional clinical and pathologic features of
DCIS remains an area of great interest.
T is study has several notable strengths. First, the present clinical
trial prospectively identified and enrolled patients with DCIS who were
selected for treatment using surgical excision without radiation on the
basis of low-risk clinical and pathologic features at presentation. Second,
patients enrolled onto this study have characteristics similar to those of
patients in population-based studies, and therefore, this study is relevant
to contemporary practice. Third, this study reports long-term follow-up
of greater than 10 years, which is especially important after treatment for
potentially lower-riskDCISbecauseof theknownriskof lateandongoing
local recurrence (Fig 1; Tables 2 and 3). Finally, there was a sufficient
number of patients to perform analyses for some clinically meaningful
patient subgroups (Tables 2 and 3).
This study has a number of potential limitations. First, the trial
designwasanonrandomizedcohort study.Thus, the impactof adding
radiation or tamoxifen after surgical excision could not be assessed.
Second, tamoxifen was administered to approximately 30% of pa-
tients in a nonrandomized fashion. Despite this limitation, tamoxifen
use was associatedwith a decreased risk of local recurrence (HR, 0.66;
P  .09), which is consistent with results from randomized clinical
trials. Third, the number of patients in cohort 2 was relatively small
(n  104), limiting the statistical power in this group of patients.
Finally, the numbers of patients in some clinically relevant subsets
were small (Tables 2 and 3).
In summary, this study has demonstrated that the risks of devel-
opingan IBEandan invasive IBE increasedover time through12years
of follow-up,withoutplateau, forpatientswithDCISof thebreastwho
were selected for favorable clinical and pathologic characteristics and
treated with surgical excision without radiation. Individual patients
and their physicians will need to decide if these 12-year risks are
acceptable, and to judge whether or not to add adjuvant treatment
after surgical excision. Not all patients and their physicians will agree
on what is considered too high a risk of developing an IBE or an
invasive IBE to recommend observation after surgical excision, or
what risk is considered too low to justify adding radiation treatment.
However, this study provides 12-year data to begin those discussions,
and to help inform the treatment decision-making process.
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Appendix
Pathology Evaluation
For the present analysis, there were data available from the central pathology review using the current College of American
Pathologists ductal carcinoma in situ guidelines.23,24 The central pathology review was performed concurrently by two expert breast
pathologists (S.S.B. and F.L.B.) for 500 patients (75% of the overall group) for whom pathology specimens were available. Ductal
carcinoma in situ pattern, grade, and comedo necrosis were scored. Of the 500 evaluated patients, 343 had undergone central pathology
review as part of a prior study.21,24 Subsequently, central pathology review was performed for 157 new patients, as well as blinded
re-evaluation of 145 previously evaluated patients. For the cases evaluated twice, grade for this study was scored as the highest grade on
either of the evaluations, and comedo necrosis was scored as present if present on either evaluation.
Patients with (n 500) and without (n 165) central pathology review were similar for distribution of cohort, age, menopausal
status, minimumnegative margin width, andmethod of detection. Tumor size in patients without central pathology review was slightly
smaller than that in patients with central pathology review (tumor size 5mm for 46% v 36%, respectively).
Table A1. Contralateral Breast Cancer Event Rates
Variable No.
5 Years 10 Years 12 Years
P% 95% CI % 95% CI % 95% CI
Contralateral breast cancer
Overall group 665 3.7 2.2 to 5.1 6.1 4.1 to 8.0 7.5 5.3 to 9.7
Cohort 1 561 3.6 2.0 to 5.2 5.3 3.4 to 7.3 6.7 4.4 to 9.0 .16
Cohort 2 104 4.0 0.2 to 7.8 10.4 3.9 to 16.9 12.0 4.9 to 19.1
Invasive contralateral breast cancer
Overall group 665 2.6 1.3 to 3.8 4.6 2.9 to 6.3 5.8 3.8 to 7.7
Cohort 1 561 2.3 1.0 to 3.6 3.8 2.1 to 5.5 4.9 2.9 to 6.9 .06
Cohort 2 104 4.0 0.2 to 7.8 9.0 3.0 to 15.0 10.6 3.9 to 17.3
DCIS-only contralateral breast cancer
Overall group 665 1.1 0.3 to 2.0 1.5 0.5 to 2.5 1.8 0.7 to 2.9
Cohort 1 561 1.3 0.4 to 2.3 1.6 0.5 to 2.6 1.8 0.6 to 3.0 .66
Cohort 2 104 0 0 to 0 1.5 0 to 4.5 1.5 0.0 to 4.5
Abbreviation: DCIS, ductal carcinoma in situ.
Table A2. IBE Rates for Clinically Relevant Subsets of Patients
Variable No.
5 Years 10 Years 12 Years
P% 95% CI % 95% CI % 95% CI
Age, years
 49 106 6.8 1.9 to 11.7 9.9 4.1 to 15.7 12.5 5.8 to 19.2 .66
50-69 312 5.1 2.6 to 7.6 12.1 8.3 to 16.0 13.9 9.8 to 18.1
 70 143 7.5 3.0 to 12.0 15.4 8.7 to 22.1 17.2 9.8 to 24.5
Minimum negative margin width, mm
 5 203 7.3 3.6 to 11.0 13.2 8.2 to 18.1 15.5 10.1 to 21.0 .87
5-9 239 5.4 2.4 to 8.3 12.1 7.6 to 16.5 14.0 9.1 to 18.9
 10 119 5.3 1.2 to 9.4 12.1 5.9 to 18.3 13.4 6.8 to 19.9
Tumor size, mm
 5 226 5.0 2.1 to 7.9 8.0 4.3 to 11.6 8.6 4.8 to 12.5  .001
6-10 231 4.3 1.5 to 7.0 14.1 9.1 to 19.1 16.9 11.4 to 22.4
 10 104 12.3 5.8 to 18.8 19.7 11.5 to 28.0 23.3 14.0 to 32.5
CAP grade†
Low 61 3.5 0 to 8.2 11.0 2.7 to 19.3 11.0 2.7 to 19.3 .61
Intermediate 249 6.4 3.3 to 9.6 12.9 8.4 to 17.4 14.9 9.9 to 19.8
High 110 6.6 1.9 to 11.4 15.9 8.7 to 23.1 15.9 8.7 to 23.1
NOTE. Analysis restricted to patients enrolled in cohort 1 (n  561).
Abbreviations: CAP, College of American Pathologists; IBE, ipsilateral breast event.
Tumor size was based on central pathology review, when this information was available.
†Restricted to the subset of cases for which a central pathology review was performed using current CAP guidelines.
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Table A3. Invasive IBE Rates for Clinically Relevant Subsets of Patients
Variable No.
5 Years 10 Years 12 Years
P% 95% CI % 95% CI % 95% CI
Age, years
 49 106 2.9 0 to 6.2 5.1 0.7 to 9.5 6.4 1.4 to 11.4 .57
50-69 312 3.4 1.3 to 5.4 6.8 3.8 to 9.7 8.1 4.8 to 11.4
 70 143 0.8 0 to 2.4 7.1 2.0 to 12.3 7.1 2.0 to 12.3
Minimum negative margin width, mm
 5 203 2.2 0.1 to 4.3 6.3 2.7 to 10.0 6.3 2.7 to 10.0 .46
5-9 239 3.1 0.8 to 5.4 7.4 3.7 to 11.0 9.4 5.2 to 13.6
 10 119 2.7 0 to 5.8 4.7 0.7 to 8.8 6.0 1.3 to 10.7
Tumor size, mm
 5 226 2.3 0.3 to 4.3 4.8 1.9 to 7.8 4.8 1.9 to 7.8 .17
6-10 231 1.9 0.1 to 3.7 7.9 4.0 to 11.7 10.0 5.5 to 14.5
 10 104 5.4 0.8 to 10.0 6.8 1.5 to 12.0 8.5 2.3 to 14.8
CAP grade†
Low 61 1.8 0 to 5.3 5.5 0 to 11.6 5.5 0 to 11.6 .69
Intermediate 249 2.2 0.3 to 4.1 5.3 2.2 to 8.3 6.6 3.1 to 10.2
High 110 2.9 0 to 6.2 9.3 3.5 to 15.2 9.3 3.5 to 15.2
NOTE. Analysis restricted to patients enrolled in cohort 1 (n  561).
Abbreviations: CAP, College of American Pathologists; IBE, ipsilateral breast event.
Tumor size was based on central pathology review, when this information was available.
†Restricted to the subset of cases for which a central pathology review was performed using current CAP guidelines.
Table A4. IBE Rates and Subset of Invasive IBE Rates Comparing Current CAP Grading to Older Grading Classifications
Variable No.
5 Years 10 Years 12 Years
P% 95% CI % 95% CI % 95% CI
IBE rates
Grade
Low 63 5.1 0 to 10.8 12.5 3.8 to 21.3 12.5 3.8 to 21.3 .16
Intermediate 268 6.3 3.3 to 9.4 13.2 8.9 to 17.6 15.1 10.4 to 19.9
High 169 11.1 6.2 to 15.9 20.6 14.2 to 27.0 20.6 14.2 to 27.0
Grade†
Low 287 5.1 2.5 to 7.7 10.5 6.7 to 14.2 12.1 8.0 to 16.2 .02
Intermediate 239 7.6 4.1 to 11.1 17.7 12.5 to 22.9 19.1 13.6 to 24.5
High 64 17.9 8.3 to 27.5 23.9 12.9 to 35.0 23.9 12.9 to 35.0
Grade‡
Low 281 5.6 2.8 to 8.3 12.3 8.2 to 16.3 14.0 9.5 to 18.4 .01
Intermediate 280 6.5 3.5 to 9.5 12.7 8.5 to 16.9 14.9 10.2 to 19.5
High 104 15.0 8.0 to 22.0 24.6 15.7 to 33.4 24.6 15.7 to 33.4
Subset of invasive IBE rates
Grade
Low 63 1.8 0 to 5.3 5.5 0 to 11.6 5.5 0 to 11.6 .19
Intermediate 268 2.0 0.3 to 3.8 5.4 2.4 to 8.4 6.7 3.2 to 10.1
High 169 4.5 1.2 to 7.7 11.7 6.4 to 17.0 11.7 6.4 to 17.0
Grade†
Low 287 1.8 0.2 to 3.4 5.3 2.5 to 8.1 5.8 2.8 to 8.8 .02
Intermediate 239 3.2 0.9 to 5.6 8.9 5.0 to 12.9 9.7 5.5 to 13.9
High 64 10.2 2.5 to 18.0 16.7 6.6 to 26.8 16.7 6.6 to 26.8
Grade‡
Low 281 1.5 0 to 3.0 5.4 2.5 to 8.3 5.9 2.9 to 9.0 .11
Intermediate 280 3.9 1.5 to 6.2 7.4 4.1 to 10.8 9.1 5.4 to 12.9
High 104 5.3 0.8 to 9.7 13.4 5.9 to 20.9 13.4 5.9 to 20.9
NOTE. Cases with unknown information were excluded from analysis.
Abbreviations: CAP, College of American Pathologists; IBE, ipsilateral breast event.
Second central pathology review using current CAP guidelines.
†First central pathology review.22
‡Institutional pathology assessment at the time of study entry.
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Table A5. IBE Rates and Subset of Invasive IBE Rates Comparing Current CAP Grading to Older Grading Classifications
Variable No.
5 Years 10 Years 12 Years
P% 95% CI % 95% CI % 95% CI
IBE rates
Grade
Low 61 3.5 0 to 8.2 11.0 2.7 to 19.3 11.0 2.7 to 19.3 .61
Intermediate 249 6.4 3.3 to 9.6 12.9 8.4 to 17.4 14.9 9.9 to 19.8
High 110 6.6 1.9 to 11.4 15.9 8.7 to 23.1 15.9 8.7 to 23.1
Grade†
Low 286 5.1 2.5 to 7.7 10.5 6.7 to 14.3 12.2 8.0 to 16.3 .25
Intermediate 191 7.9 3.9 to 11.9 17.3 11.5 to 23.1 19.0 12.9 to 25.0
High 14 7.1 0 to 20.6 15.6 0 to 35.6 15.6 0 to 35.6
Grade‡
Low 281 5.6 2.8 to 8.3 12.3 8.2 to 16.3 14.0 9.5 to 18.4 .72
Intermediate 280 6.5 3.5 to 9.5 12.7 8.5 to 16.9 14.9 10.2 to 19.5
Subset of invasive IBE rates
Grade
Low 61 1.8 0 to 5.3 5.5 0 to 11.6 5.5 0 to 11.6 .69
Intermediate 249 2.2 0.3 to 4.1 5.3 2.2 to 8.3 6.6 3.1 to 10.2
High 110 2.9 0 to 6.2 9.3 3.5 to 15.2 9.3 3.5 to 15.2
Grade†
Low 286 1.8 0.2 to 3.4 5.3 2.5 to 8.1 5.8 2.8 to 8.8 .21
Intermediate 191 4.0 1.1 to 7.0 9.1 4.7 to 13.5 10.0 5.3 to 14.7
High 14 7.1 0 to 20.6 15.6 0 to 35.6 15.6 0 to 35.6
Grade‡
Low 281 1.5 0 to 3.0 5.4 2.5 to 8.3 5.9 2.9 to 9.0 .22
Intermediate 280 3.9 0.8 to 6.2 7.4 4.1 to 10.8 9.1 5.4 to 12.9
NOTE. Analysis restricted to patients enrolled in cohort 1 (n  561). Cases with unknown information were excluded from analysis.
Abbreviations: CAP, College of American Pathologists; IBE, ipsilateral breast event.
Second central pathology review using current CAP guidelines.
†First central pathology review.22
‡Institutional pathology assessment at the time of study entry.
Solin et al
© 2015 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Downloaded from ascopubs.org by INDIANA University ACQ DEPT on April 9, 2019 from 134.068.173.162
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
0
IB
E 
In
ci
de
nc
e
Time (years)
0.5
0.4
0.3
0.2
0.1
2 4 6 8 10 12
P = .16
Low
Intermediate
High
No. at risk
Low
Intermediate
High
63
268
169
59
246
159
56
228
150
52
206
134
46
187
118
38
162
100
21
95
68
A
0
In
va
si
ve
 IB
E 
In
ci
de
nc
e
Time (years)
0.5
0.4
0.3
0.2
0.1
2 4 6 8 10 12
P = .19
Low
Intermediate
High
No. at risk
Low
Intermediate
High
63
268
169
60
248
161
57
230
152
53
210
137
48
192
121
40
168
104
21
100
72
B
Fig A1. Ipsilateral breast events (IBEs) according to grade as scored using current College of American Pathology guidelines. Analyses exclude cases not evaluated.
The numbers at risk are given beneath the x-axis. (A) Any IBE. (B) Subset of invasive IBE.
Surgical Excision Without Radiation for DCIS of the Breast
www.jco.org © 2015 by American Society of Clinical Oncology
Downloaded from ascopubs.org by INDIANA University ACQ DEPT on April 9, 2019 from 134.068.173.162
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
